Final results of the FAST study, an international,...

Annals of Oncology 2016 / 10 Vol. 27; Iss. suppl_6

Final results of the FAST study, an international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma

Schuler, M., Al-Batran, S.-E., Zvirbule, Z., Manikhas, G., Lordick, F., Rusyn, A., Vinnyk, Y., Vynnychenko, I., Fadeeva, N., Nechaeva, M., Dudov, A., Gotovkin, E., Pecheniy, A., Bazin, I., Bondarenko,
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
27
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdw371.06
Date:
October, 2016
File:
PDF, 45 KB
english, 2016
Conversion to is in progress
Conversion to is failed